Timothy Joseph Yeatman, MD

Where You Are:
Timothy Joseph Yeatman, MD

Office  (813) 745-7292

Education And Training
  • Fellow, University of Texas MD Anderson Cancer Center, 1992 - Surgical Oncology
  • Resident, University of Florida, 1990 - General Surgery
  • MD, Emory University, 1984
  • BS, Duke University, 1980


Dr. Yeatman’s research focuses on developing and validating molecular prognostic signatures in cancer, primarily in colon, lung and breast.  Initial work with mRNA expression arrays expanded to include analysis of miRNA arrays with samples from many of the same tissues. In colon cancer, gene expression changes between Duke’s stage A and D were used to define the prognosis in Duke’s stage B and C.A validation study characterized the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas; the study supported combined use of clinical and molecular information when building prognostic models for early stage lung cancer.Staging inadequately predicts metastatic risk in colon cancer patients. His team used a gene expression profile derived from invasive, murine colon cancer cells highly metastatic in an immunocompetent mouse model, to identify colon cancer patients at risk of recurrence.  The profile was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer.In research to identify the source of unknown primary tumors, Dr. Yeatman and colleagues developed a two-tiered classification scheme based on gene expression data that initially assigns a tumor to one of the four subclasses of carcinoma: adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, or urothelial carcinoma. The second tier uses one of four additional classifiers to assign the primary site of origin to the tumor.

  • Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut. 2012 Sep;61(9):1291-1298. Pubmedid: 21997556. Pmcid: PMC3419333.
  • Chen DT, Hernandez JM, Shibata D, McCarthy SM, Humphries LA, Clark W, Elahi A, Gruidl M, Coppola D, Yeatman T. Complementary Strand MicroRNAs Mediate Acquisition of Metastatic Potential in Colonic Adenocarcinoma. J Gastrointest Surg. 2012 May;16(5):905-913. Pubmedid: 22362069.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of ?-catenin. Gastroenterology. 2012 Mar;142(3):562-571.e2. Pubmedid: 22115830. Pmcid: PMC3343368.
  • Mathur R, Schaffer JD, Land WH, Heine JJ, Hernandez JM, Yeatman T. Perturbation and candidate analysis to combat overfitting of gene expression microarray data. Int J Comput Biol Drug Des. 2011 Dec;4(4):307-315. Pubmedid: 22199032.
  • Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD, Dhawan P. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology. 2011 Dec;141(6):2140-2153. Pubmedid: 21878201. Pmcid: PMC3395068.
  • Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011 Dec;103(24):1859-1870. Pubmedid: 22157961. Pmcid: PMC3243673.
  • Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, Russ P, Presley SH, Peng D, Rosenblatt DO, Haselton FR, Yang JL, Washington MK, Chen X, Eschrich S, Yeatman TJ, El-Rifai W, Beauchamp RD, Chang MS. BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. J Clin Invest. 2011 Oct;121(10):4056-4069. Pubmedid: 21911938. Pmcid: PMC3195453.
  • Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011 Sep;10(3):188-193. Pubmedid: 21855041.
  • Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A. Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. Anticancer Res. 2011 Sep;31(9):2957-2962. Pubmedid: 21868544.
  • Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl. 2011 Aug;5(7-8):383-396. Pubmedid: 21656910.
  • Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene. 2011 Jul;30(29):3234-3247. Pubmedid: 21383692.
  • Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mulé JJ. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol. 2011 Jul;179(1):37-45. Pubmedid: 21703392. Pmcid: PMC3123872.
  • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May;40(4):627-633. Pubmedid: 21499216.
  • Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D, Dai H, Yeatman TJ. EMT is the dominant program in human colon cancer. BMC Med Genomics. 2011;4:9. Pubmedid: 21251323. Pmcid: PMC3032646.
  • Nasir A, Chen DT, Gruidl M, Henderson-Jackson EB, Venkataramu C, McCarthy SM, McBride HL, Harris E, Khakpour N, Yeatman TJ. Novel molecular markers of malignancy in histologically normal and benign breast. Patholog Res Int. 2011;2011:489064. Pubmedid: 21785684. Pmcid: PMC3140260.
  • Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA. The 2010 health care reform act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res. 2010 Dec;16(24):5987-5996. Pubmedid: 21169252.
  • Henderson-Jackson EB, Helm J, Ghayouri M, Hakam A, Nasir A, Leon M, Bui M, Yeatman T, Coppola D. Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol. 2010 Oct;3(8):768-774. Pubmedid: 21151390. Pmcid: PMC2993227.
  • Chen Y, Gruidl M, Remily-Wood E, Liu RZ, Eschrich S, Lloyd M, Nasir A, Bui MM, Huang E, Shibata D, Yeatman T, Koomen JM. Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res. 2010 Aug;9(8):4215-4227. Pubmedid: 20590165. Pmcid: PMC2924816.
  • Centeno BA, Bloom G, Chen DT, Chen Z, Gruidl M, Nasir A, Yeatman TY. Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn. 2010 Jul;12(4):476-486. Pubmedid: 20558571. Pmcid: PMC2893632.
  • Melis M, Hernandez J, Siegel EM, McLoughlin JM, Ly QP, Nair RM, Lewis JM, Jensen EH, Alvarado MD, Coppola D, Eschrich S, Bloom GC, Yeatman TJ, Shibata D. Gene expression profiling of colorectal mucinous adenocarcinomas. Dis Colon Rectum. 2010 Jun;53(6):936-943. Pubmedid: 20485009.
  • Tang J, Le S, Sun L, Yan X, Zhang M, Macleod J, Leroy B, Northrup N, Ellis A, Yeatman TJ, Liang Y, Zwick ME, Zhao S. Copy number abnormalities in sporadic canine colorectal cancers. Genome Res. 2010 Mar;20(3):341-350. Pubmedid: 20086242. Pmcid: PMC2840980.
  • Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010 Mar;138(3):958-968. Pubmedid: 19914252. Pmcid: PMC3388775.
  • Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 2010 Mar;70(6):2476-2484. Pubmedid: 20197467.
  • Nam KT, Lee HJ, Smith JJ, Lapierre LA, Kamath VP, Chen X, Aronow BJ, Yeatman TJ, Bhartur SG, Calhoun BC, Condie B, Manley NR, Beauchamp RD, Coffey RJ, Goldenring JR. Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. J Clin Invest. 2010 Mar;120(3):840-849. Pubmedid: 20197623. Pmcid: PMC2827957.
  • Chen DT, Nasir A, Venkataramu C, Fulp W, Gruidl M, Yeatman T. Evaluation of malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat. 2010 Feb;120(1):25-34. Pubmedid: 19306088. Pmcid: PMC2808422.
  • Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene. 2010 Jan;29(2):305-312. Pubmedid: 19881542. Pmcid: PMC3388773.
  • Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, Bloom G, Anderson T, White J, Quackenbush J, Yeatman T. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat. 2010 Jan;119(2):335-346. Pubmedid: 19266279. Pmcid: PMC2796276.
  • Ji X, Tang J, Halberg R, Busam D, Ferriera S, Pena MM, Venkataramu C, Yeatman TJ, Zhao S. Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study. BMC Cancer. 2010;10:426. Pubmedid: 20707908.
  • Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ, Sieber OM. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res. 2009 Dec;15(24):7642-7651. Pubmedid: 19996206.
  • Nasir A, Shackelford RE, Anwar F, Yeatman TJ. Genetic risk of breast cancer. Minerva Endocrinol. 2009 Dec;34(4):295-309. Pubmedid: 20046159.
  • Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys. 2009 Oct;75(2):489-496. Pubmedid: 19735873. Pmcid: PMC3038688.
  • Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem. 2009 Jul;284(27):18210-18217. Pubmedid: 19433578. Pmcid: PMC2709385.
  • Yeatman TJ. Predictive Biomarkers: Identification and Verification. J Clin Oncol. 2009 Jun;27(17):2743-2744. Pubmedid: 19332709.
  • Xu BJ, Li J, Beauchamp RD, Shyr Y, Li M, Washington MK, Yeatman TJ, Whitehead RH, Coffey RJ, Caprioli RM. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. Mol Cell Proteomics. 2009 May;8(5):936-945. Pubmedid: 19164278. Pmcid: PMC2689774.
  • Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IP, Verspaget HW, Aaltonen LA, Kruhøffer M, Orntoft TF, Andersen CL, Sieber OM. DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res. 2008 Dec;14(24):8061-8069. Pubmedid: 19088021. Pmcid: PMC2605660.
  • Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG. Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer. 2008 Nov;113(10):2665-2670. Pubmedid: 18833585. Pmcid: PMC2614910.
  • Nair R, Siegel E, Chen D, Fulp W, Yeatman T, Malafa M, Marcet J, Shibata D. Long-Term Results of Transanal Excision After Neoadjuvant Chemoradiation for T2 and T3 Adenocarcinomas of the Rectum. J Gastrointest Surg. 2008 Oct;12(10):1797-1805. Pubmedid: 18709419.
  • Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct;15(4):288-294. Pubmedid: 18813196.
  • Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008 Oct;7(10):1780-1794. Pubmedid: 18664563. Pmcid: PMC2559938.
  • Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in oncology. Cancer Res. 2008 Sep;68(18):7250-7252. Pubmedid: 18794109.
  • Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug;14(8):822-827. Pubmedid: 18641660. Pmcid: PMC2667337.
  • Li CG, Gruidl M, Eschrich S, McCarthy S, Wang HG, Alexandrow MG, Yeatman TJ. Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosis. Int J Cancer. 2008 Jul;123(2):273-282. Pubmedid: 18464289. Pmcid: PMC2650850.
  • Yamaguchi H, Woods NT, Dorsey JF, Takahashi Y, Gjertsen NR, Yeatman T, Wu J, Wang HG. SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis. J Biol Chem. 2008 Jul;283(27):19112-19118. Pubmedid: 18474606. Pmcid: PMC2441553.
  • Kline CL, Jackson R, Engelman R, Pledger WJ, Yeatman TJ, Irby RB. Src kinase induces tumor formation in the c-SRC C57BL/6 mouse. Int J Cancer. 2008 Jun;122(12):2665-2673. Pubmedid: 18351644.
  • Elahi A, Zhang L, Yeatman T, Gery S, Sebti S, Shibata D. HPP1-mediated tumor suppression requires activation of STAT1 pathways. Int J Cancer. 2008 Apr;122(7):1567-1572. Pubmedid: 18059030.
  • Cheng A, Culhane A, Chan M, Venkataramu C, Ehrich M, Nasir A, RodriguezBA, Liu J, Yan P, Quackenbush J, Nephew K, Yeatman T, Huang T. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 2008 Mar;68(6):1786-1796. Pubmedid: 18339859.
  • Gilkes DM, Pan Y, Coppola D, Yeatman T, Reuther GW, Chen J. Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol. 2008 Mar;28(6):1999-2010. Pubmedid: 18172009.
  • Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, Wang XF. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008 Feb;22(3):308-321. Pubmedid: 18245446. Pmcid: PMC2216691.
  • Kamath V, Yeatman TJ, Eschrich SA. Toward a measure of classification complexity in gene expression signatures. Conf Proc Ieee Eng Med Biol Soc. 2008;1:5704-5707. Pubmedid: 19164012.
  • Chen DT, Schell MJ, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. J Biopharm Stat. 2008;18(5):841-852. Pubmedid: 18781520. Pmcid: PMC2717790.
  • Lockhart AC, Harris E, Lafleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol. 2008;1:1-7. Pubmedid: 21677819. Pmcid: PMC3108628.
  • Scuto A, Zhang H, Zhao H, Rivera M, Yeatman TJ, Jove R, Torres-Roca JF. RbAp48 regulates cytoskeletal organization and morphology by increasing K-Rasactivity and signaling through mitogen-activated protein kinase. Cancer Res. 2007 Nov;67(21):10317-10324. Pubmedid: 17974974.
  • Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clin Colorectal Cancer. 2007 Sep;6(9):652-656. Pubmedid: 17945038.
  • McCarthy S, Caporali A, Enkemann S, Scaltriti M, Eschrich S, Davalli P, Corti A, Lee A, Sung J, Yeatman TJ, Bettuzzi S. Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol. 2007 Sep;1(2):196-204. Pubmedid: 18521193. Pmcid: PMC2408886.
  • Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, Kong S, Sakthivel B, Xu H, Reichling T, Azhar M, Boivin GP, Roberts RB, Bissahoyo AC, Gonzales F, Bloom GC, Eschrich S, Carter SL, Aronow B, Kleimeyer J, Kleimeyer M, Ramaswamy V, Settle SH, Boone B, Levy S, Graff JM, Doetschman T, Groden J, Dove WF, Threadgill DW, Yeatman T, Coffey RJ, Aronow BJ. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 2007 Jul;8(7): R131- . Pubmedid: 17615082.
  • Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Ann Surg Oncol. 2007 Apr;14(4):1416-1423. Pubmedid: 17195911.
  • Jensen E, Kvols L, McLoughlin J, Lewis J, Alvarado M, Yeatman T, Malafa M, Shibata D. Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors. Ann Surg Oncol. 2007 Feb;14(2):780-785. Pubmedid: 17146740.
  • Bloom GC, Eschrich S, Zhou J, Coppola D, Yeatman TJ. Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer. 2007 Feb;120(4):769-775. Pubmedid: 17131332.
  • Ly Q, Yeatman T. Clinical relevance of targeted interference with Src-mediated signal transduction events. Recent Results Cancer Res. 2007;172:169-88. Pubmedid: 17607941.
  • Hodul P, Yeatman T. TNM staging is obsolete. J Surg Oncol. 2006 Dec;95(1):8-9. Pubmedid: 17192885.
  • Yan P, Venkataramu C, Ibrahim A, Liu J, Shen R, Diaz N, Centeno B, Weber F, Leu Y, Shapiro C, Eng C, Yeatman T, Huang T. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res. 2006 Nov;12(22):6626-6636. Pubmedid: 17121881.
  • Patterson S, Wei S, Chen X, Sallman D, Gilvary D, Zhong B, Pow-Sang J, Yeatman T, Djeu J. Novel role of Stat1 in the development of docetaxel resistance in prostatetumor cells. Oncogene. 2006 Oct;25(45):6113-6122. Pubmedid: 16652143.
  • Durkin AJ, Osborne DA, Yeatman TJ, Rosemurgy AS, Armstrong C, Zervos EE. EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J Surg Res. 2006 Sep;135(1):195-201. Pubmedid: 16678855.
  • Benson AB 3rd, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary B, Curley S, Davila R, Earle C, Ensminger W, Gibbs J, Laheru D, Langnas A, Mulvihill S, Nemcek AA J, Posey J, Sigurdson E, Sinanan M, Vauthey J, Venook A, WagmanLD, Yeatman T. Hepatobiliary cancers. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Aug;4(8):728-750. Pubmedid: 16948952.
  • Jensen E, McLoughlin J, Yeatman T. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand. Curr Opin Oncol. 2006 Jul;18(4):374-380. Pubmedid: 16721134.
  • Yeatman T. Carcinoembryonic antigen, biomarker discovery, and trial design. Ann Surg Oncol. 2006 May;13(5):600-601. Pubmedid: 16538403.
  • Osborne D, Zervos E, Strosberg J, Boe B, Malafa M, Rosemurgy A, Yeatman TJ, Carey L, Duhaine L, Kvols L. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006 Apr;13(4):572-581. Pubmedid: 16511671.
  • Bloomston M, Zhou J, Rosemurgy A, Frankel W, Muro-Cacho C, Yeatman T. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 2006 Mar;66(5):2592-2599. Pubmedid: 16510577.
  • Nasir A, Stridsberg M, Strosberg J, Su P, Livingston S, Malik H, Kelley ST, Centeno B, Coppola D, Malafa M, Yeatman T, Kvols L. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006 Jan;13(1):52-60. Pubmedid: 16508627.
  • Alvarado M, Jensen E, Yeatman T. The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control. 2006 Jan;13(1):27-31. Pubmedid: 16508623.
  • Cook A, Tuck A, McCarthy S, Turner J, Irby R, Bloom G, Yeatman T, Chambers A. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog. 2005 Aug;43(4):225-236. Pubmedid: 15864800.
  • Kwong K, Bloom G, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath A, Makusky A, Taylor J, Steiner S, Zhou J, Yeatman T, Quackenbush J. Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics. 2005 Aug;86(2):142-158. Pubmedid: 15951154.
  • Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, Cantor AB, Scuto A, Li C, Zhang S, Jove R, Yeatman T. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005 Aug;65(16):7169-7176. Pubmedid: 16103067.
  • Kelley S, Coppola D, Yeatman T, Marcet J. Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. Clin Colorectal Cancer. 2005 Jul;5(2):114-118. Pubmedid: 16098252.
  • Engstrom P, Benson AB 3rd, Chen Y, Choti M, Dilawari R, Enke C, FakihMG, Fuchs C, Kiel K, Knol J, Leong L, Ludwig K, Martin EW J, Rao S, Saif M, Saltz L, Skibber J, Venook A, Yeatman T. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul;3(4):468-491. Pubmedid: 16038639.
  • Engstrom P, Benson AB 3rd, Chen Y, Choti M, Dilawari R, Enke C, FakihMG, Fuchs C, Kiel K, Knol J, Leong L, Ludwig K, Martin EW J, Rao S, Saif M, Saltz L, Skibber J, Venook A, Yeatman T. Rectal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul;3(4):492-508. Pubmedid: 16038640.
  • Engstrom P, Benson AB 3rd, Chen Y, Choti M, Dilawari R, Enke C, FakihMG, Fuchs C, Kiel K, Knol J, Leong L, Ludwig K, Martin EW J, Rao S, Saif M, Saltz L, Skibber J, Venook A, Yeatman T. Anal canal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul;3(4):510-515. Pubmedid: 16038641.
  • Eschrich S, Yang I, Bloom G, Kwong K, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft T, Quackenbush J, Yeatman T. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005 May;23(15):3526-3535. Pubmedid: 15908663.
  • Helm J, Enkemann S, Coppola D, Barthel J, Kelley S, Yeatman T. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res. 2005 Apr;11(7):2478-2485. Pubmedid: 15814623.
  • Centeno B, Enkemann S, Coppola D, Huntsman S, Bloom G, Yeatman T. Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer. 2005 Apr;105(2):101-109. Pubmedid: 15643601.
  • Irby R, Malek R, Bloom G, Tsai J, Letwin N, Frank B, Verratti K, YeatmanTJ, Lee N. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Res. 2005 Mar;65(5):1814-1821. Pubmedid: 15753379.
  • Dobbin K, Beer D, Meyerson M, Yeatman T, Gerald W, Jacobson J, ConleyB, Buetow K, Heiskanen M, Simon R, Minna J, Girard L, Misek D, Taylor J, Hanash S, Naoki K, Hayes D, Ladd-Acosta C, Enkemann S, Viale A, Giordano T. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res. 2005 Jan;11(2):565-572. Pubmedid: 15701842.
  • Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, Quackenbush J, Yeatman TJ. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol. 2004 Jan;164(1):9-16. Pubmedid: 14695313.
  • Solmi R, Sanctis P, Zucchini C, Ugolini G, Rosati G, Del Governatore M, Coppola D, Yeatman T, Lenzi L, Caira A, Zanotti S, Taffurelli M, Carinci P, Valvassori L, Strippoli P. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR. Int J Oncology. 2004;25(4):1049-1056. Pubmedid: 15375555.
  • Bloomston M, Durkin A, Yang I, Rojiani M, Rosemurgy A, Enkmann S, Yeatman TJ, Zervos E. Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies. Ann Surg Oncol. 2004;11(4):413-419. Pubmedid: 15070602.
  • Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers A, Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10(1):184-190. Pubmedid: 14734468.
  • Nasir A, Kaiser H, Boulware D, Hakam A, Zhao H, Yeatman T, Barthel J, Coppola D. Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer. 2004;3(4):243-247. Pubmedid: 15025797.
  • Irby R, McCarthy S, Yeatman T. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis. 2004;21(6):515-523. Pubmedid: 15679049.
  • Durkin AJ, Bloomston PM, Rosemurgy AS, Giarelli N, Cojita D, Yeatman TJ, Zervos EE. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg. 2003 Nov;186(5):431-436. Pubmedid: 14599602.
  • Yeatman T. The future of cancer management: translating the genome, transcriptome, and proteome. Ann Surg Oncol. 2003;10(1):7-14. Pubmedid: 12513953.
  • Yeatman T, Chambers A. Osteopontin and colon cancer progression. Clin Exp Metastasis. 2003;20(1):85-90. Pubmedid: 12650611.
  • Chen T, Yang I, Irby R, Shain K, Wang H, Quackenbush J, Coppola D, Cheng JQ, Yeatman T. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 2003;63(15):4368-4374. Pubmedid: 12907606.
  • Yeatman T. Beyond p53. Ann Surg Oncol. 2003;10:831-831. Pubmedid: 14527897.
  • Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003;34(8):803-808. Pubmedid: 14506643.
  • Yeatman T. The future of clinical cancer management: one tumor, one chip. Am Surg. 2003;69(1):41-44. Pubmedid: 12575779.
  • Agrawal D, Chen T, Irby R, Quackenbush J, Chambers A, Szabo M, Cantor A, Coppola D, Yeatman T. Osteopontin identified as colon cancer tumor progression marker. C R Biol. 2003;326(10-11):1041-1043. Pubmedid: 14744111.
  • Yang IV, Chen E, Hasseman JP, Liang W, Frank BC, Wang S, Sharov V, Saeed AI, White J, Li J, Lee NH, Yeatman TJ, Quackenbush J. Within the fold: assessing differential expression measures and reproducibility in microarray assays. Genome Biol. 2002 Oct;3(11):0062-0062. Pubmedid: 12429061.
  • Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D. Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer. 2002 Aug;2(2):119-122. Pubmedid: 12453327.
  • Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res. 2002 May;62(9):2669-2674. Pubmedid: 11980666.
  • Malek R, Irby R, Guo Q, Lee K, Wong S, He M, Tsai J, Frank B, Liu E, Quackenbush J, Jove R, Yeatman T, Lee N. Identification of Src transformation fingerprint in human colon cancer. Oncogene. 2002;21(47):7256-7265. Pubmedid: 12370817.
  • Kim C, Reintgen D, Yeatman T. The promise of microarray technology in melanoma care. Cancer Control. 2002;9(1):49-53. Pubmedid: 11907466.
  • Agrawal D, Chen T, Irby R, Quackenbush J, Chambers A, Szabo M, Cantor A, Coppola D, Yeatman T. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94(7):513-521. Pubmedid: 11929952.
  • Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001 Jun;98(13):7319-7324. Pubmedid: 11404481.
  • Hegde P, Qi R, Gaspard R, Abernathy K, Dharap S, Earle-Hughes J, Gay C, Nwokekeh N, Chen T, Saeed A, Sharov V, Lee N, Yeatman T, Quakenbush J. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res. 2001;61(21):7792-7797. Pubmedid: 11691794.
  • Huang J, Qi R, Quackenbush J, Dauway E, Lazaridis E, Yeatman T. Effects of ischemia on gene expression. J Surg Res. 2001;99(2):222-227. Pubmedid: 11469890.
  • Teng S, Sun J, Irby R, Hamilton A, Sebti S, Yeatman T. V-Src transformation is mediated through farnesylated protein. J Surg Res. 2001;99(2):343-346. Pubmedid: 11469908.
  • Kim C, Yeatman T, Coppola D, Trotti A, Williams B, Barthel J, Dinwoodie W, Karl R, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234(3):352-358. Pubmedid: 11524588.
  • Yeatman T. Nutritional support for the surgical oncology patient. Cancer Control. 2000;7(6):563-565. Pubmedid: 11088065.
  • Irby R, Yeatman T. Role of Src expression and activation in human cancer. Oncogene. 2000;19(49):5636-5642. Pubmedid: 11114744.
  • Yeatman T, Cox C. The significance of breast cancer lymph node micrometastases. Clin North Amer. 1999;8(3):481-496. Pubmedid: 10448691.
  • Yeatman T, Moazam F, Talbert J. Evaluation and treatment of an unusual neck mass in a child. Surg Rounds. 1999;22(2):77-79.
  • Irby R, Mao W, Coppola D, Kang J, Trudeau W, Loubeau J, Karl R, Fujita D, Jove R, Yeatman T. Identification of an activating c-Src mutation with transforming and metastatic properties in human colon cancer. Nat Genet. 1999;21(2):187-190. Pubmedid: 9988270.
  • Cox C, Yeatman T, Salus C, Bass S. Significance of sentinel node micrometastasis. Cancer Control. 1999;6(6):601-605. Pubmedid: 10756392.
  • Haddad F, Yeatman T, Reintgen D, Shivers S. The human genome project: a dream becoming a reality. Surgery. 1999;126(6):575-580. Pubmedid: 10372021.
  • Hakam A, Yeatman T, Lu L, Mora L, Marcet J, Nicosia S, Karl R, Coppola D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999;30(10):1128-1133. Pubmedid: 10534157.
  • Iravani S, Mao W, Fu L, Karl R, Yeatman T, Jove R, Coppola D. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest. 1998 Mar;78(3):365-371. Pubmedid: 9520949 .
  • Coppola D, Lu L, Fruehauf J, Kyshtoobayeva A, Karl R, Nocosia S, Yeatman T. Analysis of p53, p21WAF1 and TFG-beta1 in human ductal adenocarcinoma of the pancreas: TFG-beta1 protein. Am J Clin Pathol. 1998;110(1):16-23. Pubmedid: 9661918.
  • Iravani S, Mao W, Fu I, Jove R, Yeatman T, Karl R, Coppola D. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest. 1998;78(3):365-371. Pubmedid: 9520949.
  • Cox C, Huddad F, Bass S, Cox J, Ku N, Berman C, Shons A, Pendas S, Reintgen D, Yeatman T. Lymphatic mapping in the treatment of breast cancer. Oncology. 1998;12(9):1283-1298. Pubmedid: 9778675.
  • Paredes-Zaglul A, Kang J, Essig Y, Mao W, Irby I, Wloch M, Yeatman T. Analysis of colorectal cancer by comparative genomic hybridization: evidence for induction of the metastatic phenotype by loss of tumor suppressor genes. Clin Cancer Res. 1998;4(4):879-886. Pubmedid: 9563881.
  • Cox C, Pendas S, Cox J, Joseph E, Shons A, Yeatman T, Ku N, Lyman G, Berman C, Haddad F, Reintgen D. Guidelines for sentinel node biopsy and lymphatic mapping of breast cancer patients. Ann Surg. 1998;227(5):645-645. Pubmedid: 9605656.
  • Huffman J, Yeatman T, Smith J. Leptomeningeal carcinomatosis: a sequela of cholangiocarcinoma. Am Surg. 1997;63:310-313. Pubmedid: 9124747.
  • Reintgen D, Joseph E, Lyman G, Yeatman T, Balducci L, Ku N, Berman C, Shons A, Wells K, Horton J, Greenberg H, Nicosia S, Clark R, Shivers S, Li W, Wang X, Cantor A, Cox C. The role of selective lymphadenectomy in breast cancer. Cancer Control. 1997;4(3):211-219. Pubmedid: 10763020.
  • Irby R, Mao W, Coppola D, Jove R, Gamero A, Cuthbertson D, Fujita D, Yeatman T. Overexpression of normal c-Src in poorly-metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential. Cell Growth Differ. 1997;8:1287-1295. Pubmedid: 9419417.
  • Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman T. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene. 1997;15:3083-3090. Pubmedid: 9444956.
  • Karl R, Choi J, Yeatman T, Clark R. Role of computed tomographic arterial portography (CTAP) and intraoperative ultrasound (IOUS) in the evaluation of patients for resectability of hepatic lesions. J Gastro Surg. 1997;1(2):152-158. Pubmedid: 9834342.
  • Yeatman T, Mao W, Karl R. Biliary glycoprotein is overexpressed in liVer-metastatic human colon cancer cells. J Gastro Surg. 1997;1(3):292-298. Pubmedid: 9834361.
  • Yeatman T, Lyman G, Smith S, Reintgen D, Cantor A, Cox C. Bilaterality and recurrance rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol. 1997;4(3):198-202. Pubmedid: 9142379.
  • Marcet J, Yeatman T. Avoiding colostomy with conservative multimodalilty management of distal rectal cancer. Cancer Control. 1996;3(1):26-33. Pubmedid: 10825273.
  • Albertini J, Lyman G, Cox C, Yeatman T, Balducci L, Ku N, Shivers S, Berman C, Wells K, Rapaport D, Shons A, Horton J, Greenberg H, Nicosia S, Clark R, Cantor A, Reintgen D. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. Jama. 1996;276(22):1818-1822. Pubmedid: 8946902.
  • Mao W, Yeatman T, Karl R, Jove R. c-Src activation by epidermal growth factor through receptor family kinases may potentiate human colon cancer liver metastasis. Surg Forum. 1996;67:507-510.
  • Yeatman T, Duan C, Mao W, Karl R, Djeu J. Augmentation of carcinoembryonic antigen release from intact, viable, tumor cells by a factor in human serum. Ann Surg Oncol. 1995;2(4):336-342. Pubmedid: 7552624.
  • Yeatman T, Cantor A, Smith T, Smith S, Reintgen D, Miller M, Ku N, Baekey P, Cox C. Tumor biology of infiltrating lobular carcinoma. Ann Surg. 1995;222(4):549-559. Pubmedid: 7574934.
  • Yeatman T, Karl R. Molecular basis for chemoprevention of colorectal carcinogenesis. J Fla Med Assoc. 1995;82(5):360-363. Pubmedid: 7602310.
  • Yeatman T, Mao W. Identification of a differentially-expressed message associated with colon cancer liver metastasis using an improved method of differential display. Nucleic Acids Res. 1995;23(19):4007-4008. Pubmedid: 7479054.
  • Yeatman T, Mao W, Karl R, Djeu J. Phospholipase C-gamma is present on the surface of human colorectal cancer cells. Biochem Biophys Res Commun. 1994;201(2):1043-1049.
  • Yeatman T, Mao W, Karl R, Djeu J. Phospholiase C-gamma is present on the surface of human colerectal cancer cells. Biochem Biophys Res Commun. 1994;201(2):1043-1049.
  • Yeatman T, Copeland E. CEA directed second-look surgery. In: Cameron J, ed. Current Surgical Therapies. 5th ed. 1994;195-199.
  • Tressler R, Yeatman T, Nicolson G. Extracellular annexin VI expression is associated with divalentcation-dependent endothial cell adhesion of metastatic RAW 117 large-cell lymphoma cells. Exp Cell Res. 1994;215:395-400.
  • Yeatman T, Updyke T, Dedman J, Nicolson G. Expression of annexins on the surfaces of nonmetastatic and metastatic human and rodent tumor cells. Clin Exp Metastasis. 1993;11(1):37-44.
  • Kim E, Podoloff D, Yeatman T, Moulopoulos L, Hortobagyi G, Singletary S. Imaging resonance imaging, positron emission tomography and radio-immunoscintigraphy of breast cancer. Cancer Bull. 1993;45(6):500-505.
  • Yeatman T, Nicolson G. The molecular basis of tumor progression: the mechanism of organ-specific tumor metastasis. Semin Surg Oncol. 1993;9:256-263.
  • Tressler R, Updyke T, Yeatman T, Nicolsom G. Extracellular annexin II is associated with divalent- cation-dependent tumor cell-endothelial cell-adhesion of metastatic RAW 117 large-cell lymphoma cells. J Cell Biol. 1993;53:265-276.
  • Yeatman T, Weber R, Balch C. The comtemporary management of skin cancers. In: Levine B, Copeland E, Warshaw A, Howard R, et al, eds. Current Practice of Surgery. New York, NY: Churchill Livingstone; 1993.
  • Karl R, Yeatman T. Molecular screening and prevention of colon cancer. In: Reintgen D, Clark R, eds. Cancer Screening. St. Louis. Mosby Yearbook, Inc.; 1996;221-238.
  • Yeatman T. The natural history of locally advanced primary breast cancer and metastic disease. In: Bland K, ed. Surgical oncology clinics of north america. Philadelphia. WB Saunders; 1995;569-589.
  • Yeatman T, Bland D. Operative considerations II: sphincter-saving procedures for operable rectal cancer. In: Cohen A, Winawer S, eds. Cancer of the Colon, Rectum and Anus. New York, NY: McGraw Hill; 1994;571-577.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer